PYC Therapeutics (PYC) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with confirmation of quorum and introduction of board members and company secretary.

• Chair outlined the process for voting and proxy handling, with 43% of issued capital represented.

Board and executive committee updates

• Announced new executive appointments, including a new CFO and Joint Company Secretary.

• Plans to expand the board to six directors, with a focus on building skills for increased company complexity.

• Emphasis on strengthening the executive team, particularly in the U.S., to support clinical development and regulatory engagement.

Shareholder proposals

• Approval sought for the Rights Plan, increase in non-executive director remuneration cap, and issuance of options to the CEO.

• Detailed rationale provided for each resolution, including benchmarking and alignment with company growth.